News | Brachytherapy Systems | December 29, 2020

Brachytherapy Planning and a Speed Revolution in Proton Monte Carlo Dose Computation

RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.

December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.

In line with the company’s aim of integrating with as many treatment delivery systems as possible, the new release includes support for high-dose-rate (HDR) brachytherapy planning. RayStation 10B features automatic channel reconstruction in combination with powerful dwell-time optimization, enabling faster and more consistent creation of high-quality brachytherapy plans. The efficiency and possibilities of brachytherapy planning are further enhanced by tools for working with multiple image sets, image deformation and dose summation. 

HDR brachytherapy is a radiation therapy technique in which a small radioactive source is placed at different positions inside the patient to obtain an advantageous dose distribution. High doses can be delivered to tumors while sparing organs at risk. The technique is used, for example, to treat gynecological, prostate, breast, head-and-neck and skin cancers.

Another notable addition in RayStation 10B is the multi-GPU Monte Carlo dose engine for proton planning. With typical final dose computation times of less than five seconds, the GPU Monte Carlo algorithm is expected to revolutionize planning workflows at proton clinics. The physics algorithms of the GPU proton Monte Carlo dose engine are identical to those in the now well-established RayStation CPU proton Monte Carlo dose engine, and dosimetric results are equally strong.

Machine-learning capabilities were introduced in RayStation 8B and are being continuously improved with each successive release. In RayStation 10B, machine learning applications further increase efficiency and improve consistency for photon and robust proton planning, and deep-learning organ segmentation. 

The robust optimization framework has been extended to take intra- and inter-fractional motion into account, with consideration for motion during the delivery of single fractions and changes over the entire treatment course. This framework supports improved plan quality, for example in cases with organ motion. 10B also introduces machine parameter improvements to utilize the full potential of the most common linacs. As a result, it is now possible to create treatment plans with more conformal dose distribution and lower dose to organs at risk.

Other enhancements include closer integration with the oncology information system RayCare. When running RayStation in a RayCare environment, the planning task list is now accessible in RayStation for improved workflow management.

Johan Löf, CEO of RaySearch, said: “Each release of RayStation takes clinical workflows to the next level. Brachytherapy is a highly accurate technique, and the capabilities of our advanced software will bring a new dimension to the treatment of several cancer types.”

For more information: www.raysearchlabs.com

Related Content

Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.
News | Women's Health | April 08, 2021
April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage F
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
The National Comprehensive Cancer Network® (NCCN®) and the American Cancer Society (ACS) are teaming up with leading health organizations across the country to endorse the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
News | Radiation Therapy | March 31, 2021
March 31, 2021 — Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanc
Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Lung Imaging | March 29, 2021
March 29, 2021 — According to ARRS' 
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

News | Radiopharmaceuticals and Tracers | March 26, 2021
March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of
Cancer tissue being bombarded by targeted alpha particles. The generator developed by Los Alamos National Laboratory holds uranium-230, which decays to thorium-226. Further decay produces short-lived daughter isotopes, emitting four more alpha particles resulting in a very high combined radiation dose to destroy cancer cells.

Cancer tissue being bombarded by targeted alpha particles. The generator developed by Los Alamos National Laboratory holds uranium-230, which decays to thorium-226. Further decay produces short-lived daughter isotopes, emitting four more alpha particles resulting in a very high combined radiation dose to destroy cancer cells.

News | Radiation Therapy | March 23, 2021
March 23, 2021 — Improved options for cancer treatment...